Clinical characteristics and outcomes of patients with overlapping Miller Fisher syndrome and myasthenia gravis

摘要

Myasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness and fatigue, which is caused by autoantibodies directed against acetylcholine receptors (AChR) at the neuromuscular junction [ ]. The prognosis is relatively favorable with optimum symptomatic, immunosuppressive and supportive treatment. Pyridostigmine is the preferred symptomatic treatment, and corticosteroids, azathioprine and thymectomy are first-line immunosuppressive therapies [ ].